Intermittent Fasting Versus Carbohydrate Drinks Before Surgery
Launched by ACADEMISCH MEDISCH CENTRUM - UNIVERSITEIT VAN AMSTERDAM (AMC-UVA) · Feb 27, 2023
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is exploring whether a method called intermittent fasting, where you eat only during certain hours, can help improve insulin resistance in patients preparing for orthopedic surgery. Insulin resistance means your body has a harder time using insulin properly, which can be important for managing blood sugar levels, especially around the time of surgery. The study compares this fasting approach to the traditional method of drinking carbohydrate-rich beverages before surgery.
To participate in this trial, you should be between 65 and 74 years old and scheduled for elective orthopedic surgery that is considered intermediate to complex. You also need to be motivated to follow a time-restricted eating schedule and able to give your consent. However, if you have diabetes, certain eating disorders, or other specific health issues, you may not be eligible. If you join the study, you can expect to follow the fasting regimen and participate in assessments related to your health and surgery. This research could provide valuable insights into optimizing care for patients undergoing surgery.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Undergoing elective orthopaedic surgery;
- • Intermediate, major or complex surgery according to the Surgical Outcome Risk Tool (SORT; http://www.sortsurgery.com/) severity of surgery classification;
- • Scheduled for surgery at least 17 days from the date of screening;
- • Motivated to follow a time restricted feeding regimen.
- • Willing and able to provide written informed consent.
- Exclusion Criteria:
- • History of diabetes mellitus;
- • History of feeding or eating disorders;
- • History of delayed gastric emptying or gastro-oesophageal reflux
- • Active malignancy
- • Patients classified as ASA IV by the attending anaesthetist;
- • BMI \< 18.5 or ≥ 35;
- • Outpatient or day case surgery;
- • Palliative surgery;
- • Participation in another clinical trial that is interfering with the procedures or outcomes of the PRINCESS trial;
- • Patients unable to fully comply to study needs (e.g. legally incapable patients or patients unable to communicate in Dutch).
About Academisch Medisch Centrum Universiteit Van Amsterdam (Amc Uva)
The Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) is a leading academic medical center in the Netherlands, dedicated to advancing healthcare through innovative research, education, and patient care. Affiliated with the University of Amsterdam, AMC-UvA integrates clinical practice with cutting-edge biomedical research, fostering a multidisciplinary approach to medical challenges. The institution actively engages in clinical trials to enhance treatment options and improve patient outcomes, while promoting collaboration among healthcare professionals, researchers, and academic institutions globally. With a commitment to excellence and a focus on translational medicine, AMC-UvA plays a pivotal role in shaping the future of healthcare.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Amsterdam, Noord Holland, Netherlands
Patients applied
Trial Officials
Jeroen Hermanides, MSc
Principal Investigator
Amsterdam UMC, location AMC
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials